HBM Healthcare Investments 2021 Biotech Portfolio Presentation

HBM Healthcare Investments presents its strategy of investing in private and public life science companies with innovative platforms and drug candidates in clinical development. The presentation highlights 2020 achievements including 10 IPOs, 6 trade sales, and 6 drug approvals, with portfolio companies focused on emerging biotech innovations including gene editing, cell therapy, and next-generation biologics.